White House reviews FDA's new prescription drug user fee agreement for 2028-2032

The White House is currently reviewing a recently negotiated agreement between the FDA and the biopharma industry that determines the level of prescription-drug user fees for the period 2028 through 2032.

The deal, reached earlier this year, includes higher fees for manufacturers but also incorporates incentives such as faster review timelines for certain products, aiming to balance agency funding with industry needs.

Industry observers note that the agreement could affect budgeting and pricing strategies for companies, while policymakers stress the importance of maintaining a robust FDA budget to support drug safety and innovation.

The review process is expected to conclude before the next fiscal cycle, after which the finalized fee schedule will be implemented.